← Eichor
Study identifier: NCT06216808 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension

Condition: Resistant Hypertension  ·  Sponsor: DeepQure Inc.

PhaseNA
Planned participants10
Who can joinAll sexes, 19 Years to 79 Years
Healthy volunteersNo

About this study

HQ-HTN-K01-02 is a prospective, multicenter, single arm, open label, first-in-human study to evaluate the safety and initial efficacy of HyperQureTM, laparoscopic denervation therapy, in patients with resistant hypertension on 3 or more antihypertensive medications

This description comes directly from the study's public registry record.

Talk to the study team

Aeyoung Woo  ·  82-10-7109-0205  ·  aywoo@deepqure.com

Always discuss trial participation with your own doctor first.

Locations (7)

Chonnam National University Hospital Hwasun HospitalJeonam, Chonnam Province, South KoreaRecruiting
Seoul National University Bundang HospitalGyeonggi-do, South KoreaRecruiting
Asan Medical CenterSeoul, South KoreaRecruiting
Hanyang University Seoul HospitalSeoul, South KoreaRecruiting
Seoul National University HospitalSeoul, South KoreaRecruiting
The Catholic University of Korea, Seoul St. Mary's HospitalSeoul, South KoreaRecruiting
Yonsei University Health System, Severance HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06216808